Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants later this year.

We believe there is minimal cause for concern with LLY stock, which makes it attractive but highly sensitive to adverse events as its current valuation is extremely ...

Eli Lilly (LLY) and Company announced at plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States.

FDA-approved medicines," Eli Lilly CEO Dave Ricks said in a statement Wednesday. The company began building out capacity as demand for its blockbuster GLP-1 products — Mounjaro for diabetes and ...